Cargando…

Clinical outcomes and patterns of care in the treatment of carcinosarcoma of the breast

PURPOSE: Carcinosarcoma of the breast is a rare yet highly aggressive tumor accounting for <1% of all breast cancers, for which guidance on optimal management and prognosis are sparse. The purpose of this study was to investigate population‐based treatment patterns and overall survival (OS) outco...

Descripción completa

Detalles Bibliográficos
Autores principales: Kennedy, William R., Gabani, Prashant, Acharya, Sahaja, Thomas, Maria A., Zoberi, Imran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488124/
https://www.ncbi.nlm.nih.gov/pubmed/30864198
http://dx.doi.org/10.1002/cam4.1942
_version_ 1783414604757467136
author Kennedy, William R.
Gabani, Prashant
Acharya, Sahaja
Thomas, Maria A.
Zoberi, Imran
author_facet Kennedy, William R.
Gabani, Prashant
Acharya, Sahaja
Thomas, Maria A.
Zoberi, Imran
author_sort Kennedy, William R.
collection PubMed
description PURPOSE: Carcinosarcoma of the breast is a rare yet highly aggressive tumor accounting for <1% of all breast cancers, for which guidance on optimal management and prognosis are sparse. The purpose of this study was to investigate population‐based treatment patterns and overall survival (OS) outcomes in patients with this diagnosis. MATERIALS AND METHODS: We queried the National Cancer Database for patients diagnosed with carcinosarcoma of the breast. All patients included were treated with surgery in the form of mastectomy or lumpectomy, with or without chemotherapy and/or radiation therapy. Patients with metastatic disease were excluded. Kaplan‐Meier analysis was used to estimate OS. Univariate and multivariable Cox analyses were used to determine predictive factors of OS. RESULTS: A total of 329 patients from 2004 to 2012 were identified. Median age at diagnosis was 58 years (range, 24‐90). Patients had T1 (21%), T2 (44%), T3 (25%), or T4 disease (10%). Most patients were node‐negative at diagnosis (77%). Breast conservation surgery was utilized in 33% of patients. Chemotherapy was used in 66% of patients. Less than half (44%) of patients received radiation therapy to a median dose of 50.4 Gy (range 35‐56 Gy), with a median 10 Gy boost used in 76%. With a median follow‐up of 40.0 months, 3‐ and 5‐year OS for all patients was 74% and 60%, respectively. Kaplan‐Meier estimates revealed the 3‐yr OS was 80% in patients receiving chemotherapy vs 59% without chemotherapy (P < 0.001). The 3‐yr OS was 82% in patients receiving RT vs 66% without RT (P = 0.001). On multivariable analysis, OS was significantly influenced by Charlson‐Deyo comorbidity index, insurance status, clinical T stage, surgical margin status, and treatment group, with trimodality therapy (HR: 0.45, 95% CI: 0.27‐0.78; P = 0.004) and surgery plus CT (HR: 0.54, 95% CI: 0.33‐0.90; P = 0.02) being associated with the greatest OS. Logistic regression revealed only younger patients were more likely to receive trimodality therapy. CONCLUSIONS: Carcinosarcoma of the breast is associated with relatively poor rates of OS. The addition of CT and RT to surgery improves OS. Trimodality therapy and surgery plus CT were associated with the greatest OS compared to surgery alone.
format Online
Article
Text
id pubmed-6488124
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64881242019-05-23 Clinical outcomes and patterns of care in the treatment of carcinosarcoma of the breast Kennedy, William R. Gabani, Prashant Acharya, Sahaja Thomas, Maria A. Zoberi, Imran Cancer Med Clinical Cancer Research PURPOSE: Carcinosarcoma of the breast is a rare yet highly aggressive tumor accounting for <1% of all breast cancers, for which guidance on optimal management and prognosis are sparse. The purpose of this study was to investigate population‐based treatment patterns and overall survival (OS) outcomes in patients with this diagnosis. MATERIALS AND METHODS: We queried the National Cancer Database for patients diagnosed with carcinosarcoma of the breast. All patients included were treated with surgery in the form of mastectomy or lumpectomy, with or without chemotherapy and/or radiation therapy. Patients with metastatic disease were excluded. Kaplan‐Meier analysis was used to estimate OS. Univariate and multivariable Cox analyses were used to determine predictive factors of OS. RESULTS: A total of 329 patients from 2004 to 2012 were identified. Median age at diagnosis was 58 years (range, 24‐90). Patients had T1 (21%), T2 (44%), T3 (25%), or T4 disease (10%). Most patients were node‐negative at diagnosis (77%). Breast conservation surgery was utilized in 33% of patients. Chemotherapy was used in 66% of patients. Less than half (44%) of patients received radiation therapy to a median dose of 50.4 Gy (range 35‐56 Gy), with a median 10 Gy boost used in 76%. With a median follow‐up of 40.0 months, 3‐ and 5‐year OS for all patients was 74% and 60%, respectively. Kaplan‐Meier estimates revealed the 3‐yr OS was 80% in patients receiving chemotherapy vs 59% without chemotherapy (P < 0.001). The 3‐yr OS was 82% in patients receiving RT vs 66% without RT (P = 0.001). On multivariable analysis, OS was significantly influenced by Charlson‐Deyo comorbidity index, insurance status, clinical T stage, surgical margin status, and treatment group, with trimodality therapy (HR: 0.45, 95% CI: 0.27‐0.78; P = 0.004) and surgery plus CT (HR: 0.54, 95% CI: 0.33‐0.90; P = 0.02) being associated with the greatest OS. Logistic regression revealed only younger patients were more likely to receive trimodality therapy. CONCLUSIONS: Carcinosarcoma of the breast is associated with relatively poor rates of OS. The addition of CT and RT to surgery improves OS. Trimodality therapy and surgery plus CT were associated with the greatest OS compared to surgery alone. John Wiley and Sons Inc. 2019-03-12 /pmc/articles/PMC6488124/ /pubmed/30864198 http://dx.doi.org/10.1002/cam4.1942 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Kennedy, William R.
Gabani, Prashant
Acharya, Sahaja
Thomas, Maria A.
Zoberi, Imran
Clinical outcomes and patterns of care in the treatment of carcinosarcoma of the breast
title Clinical outcomes and patterns of care in the treatment of carcinosarcoma of the breast
title_full Clinical outcomes and patterns of care in the treatment of carcinosarcoma of the breast
title_fullStr Clinical outcomes and patterns of care in the treatment of carcinosarcoma of the breast
title_full_unstemmed Clinical outcomes and patterns of care in the treatment of carcinosarcoma of the breast
title_short Clinical outcomes and patterns of care in the treatment of carcinosarcoma of the breast
title_sort clinical outcomes and patterns of care in the treatment of carcinosarcoma of the breast
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6488124/
https://www.ncbi.nlm.nih.gov/pubmed/30864198
http://dx.doi.org/10.1002/cam4.1942
work_keys_str_mv AT kennedywilliamr clinicaloutcomesandpatternsofcareinthetreatmentofcarcinosarcomaofthebreast
AT gabaniprashant clinicaloutcomesandpatternsofcareinthetreatmentofcarcinosarcomaofthebreast
AT acharyasahaja clinicaloutcomesandpatternsofcareinthetreatmentofcarcinosarcomaofthebreast
AT thomasmariaa clinicaloutcomesandpatternsofcareinthetreatmentofcarcinosarcomaofthebreast
AT zoberiimran clinicaloutcomesandpatternsofcareinthetreatmentofcarcinosarcomaofthebreast